|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.750 CAD | -2.14% |
|
-4.18% | -4.84% |
| Jul. 16 | High Tide Closes $30 Million Cronos Group Convertible Debt | MT |
| Jul. 15 | High Tide Inc. announced that it has received CAD 30 million in funding from Cronos Group Inc. | CI |
| Capitalization | 1.06B 772M 663M 617M 574M 66.52B 1.18B 7.46B 2.82B 31.19B 2.9B 2.84B 115B | P/E ratio 2025 * |
-32.9x | P/E ratio 2026 * | - |
|---|---|---|---|---|---|
| Enterprise value | 1.06B 772M 663M 617M 574M 66.52B 1.18B 7.46B 2.82B 31.19B 2.9B 2.84B 115B | EV / Sales 2025 * |
5.19x | EV / Sales 2026 * | - |
| Free-Float |
52.38% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Cronos Group Inc.
More recommendations
More press releases
More news
| 1 day | -2.14% | ||
| 1 week | -4.18% | ||
| Current month | +5.36% | ||
| 1 month | +5.77% | ||
| 3 months | +13.17% | ||
| 6 months | -4.18% | ||
| Current year | -4.84% |
| 1 week | 2.73 |  | 2.91 |
| 1 month | 2.54 | | 2.95 |
| Current year | 2.27 | | 3.04 |
| 1 year | 2.27 | | 3.5 |
| 3 years | 2.14 | | 4.88 |
| 5 years | 2.14 | | 20.08 |
| 10 years | 0.14 | | 32.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 38 | 2022-03-20 | |
Anna Shlimak
DFI | Director of Finance/CFO | 39 | 2025-03-18 |
Arye Weigensberg
CTO | Chief Tech/Sci/R&D Officer | 42 | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 38 | 2017-03-01 | |
Jason Adler
BRD | Director/Board Member | 53 | 2016-07-11 |
James Rudyk
BRD | Director/Board Member | 58 | 2018-01-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.14% | -4.18% | -15.64% | -28.94% | 772M | ||
| +0.48% | -1.44% | -6.05% | +30.21% | 4.46B | ||
| -0.33% | +5.26% | -15.83% | +9.96% | 3.54B | ||
| +0.26% | +1.88% | -5.24% | -40.81% | 3.54B | ||
| +1.93% | +9.86% | +6.64% | +53.34% | 3.39B | ||
| +0.19% | +2.21% | +23.57% | +55.77% | 3.37B | ||
| -0.44% | +6.10% | +17.91% | -6.72% | 2.64B | ||
| -0.13% | -0.31% | -2.56% | +92.50% | 1.79B | ||
| -0.91% | -1.86% | +27.41% | +89.16% | 1.78B | ||
| -0.17% | +2.54% | +20.20% | -6.47% | 1.7B | ||
| Average | -0.13% | +2.00% | +5.04% | +24.80% | 2.7B | |
| Weighted average by Cap. | +0.15% | +2.79% | +4.23% | +24.76% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 204M 149M 128M 119M 111M 12.82B 228M 1.44B 543M 6.01B 558M 547M 22.09B | - |
| Net income | -31.94M -23.28M -19.97M -18.61M -17.31M -2B -35.67M -225M -84.86M -940M -87.31M -85.5M -3.45B | - |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
459
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-07-18 | 2.750 $ | -2.14% | 88,866 |
| 25-07-17 | 2.810 $ | +2.18% | 46,472 |
| 25-07-16 | 2.750 $ | -0.36% | 102,474 |
| 25-07-15 | 2.760 $ | -2.13% | 65,702 |
| 25-07-14 | 2.820 $ | -1.74% | 171,135 |
Delayed Quote Toronto S.E., July 18, 2025 at 04:00 pm EDT
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
2.750CAD
Average target price
4.083CAD
Spread / Average Target
+48.48%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CRON Stock
Select your edition
All financial news and data tailored to specific country editions
